Last reviewed · How we verify

ANRS, Emerging Infectious Diseases — Portfolio Competitive Intelligence Brief

ANRS, Emerging Infectious Diseases pipeline: 11 marketed, 0 filed, 15 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 15 Phase 3 15 Phase 2 22 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Rifampin, isoniazid, pyrazinamide, ethambutol Rifampin, isoniazid, pyrazinamide, ethambutol marketed Anti-tuberculosis agent (fixed-dose combination) Multiple: RNA polymerase (rifampin), mycolic acid synthesis (isoniazid), arabinosyl transferases (ethambutol), pyrazinamidase/nicotinamidase (pyrazinamide) Infectious Disease
Ervebo Ervebo marketed Other
Inmazeb Inmazeb marketed Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein Immunology
Sofosbuvir and Daclatasvir for 24 weeks Sofosbuvir and Daclatasvir for 24 weeks marketed Direct-acting antiviral (DAA) combination HCV NS5B RNA polymerase and HCV NS5A protein Infectious Disease / Virology
Antiretroviral therapy Antiretroviral therapy marketed Combination antiretroviral therapy (multiple classes: nucleoside/nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors, entry inhibitors) HIV reverse transcriptase, HIV integrase, HIV protease, HIV envelope glycoproteins (gp120/gp41), CCR5 co-receptor Infectious Disease / Virology
blood sampling blood sampling marketed Diagnostics / Infectious Disease Surveillance
Fumarate, Tenofovir Disoproxil Fumarate, Tenofovir Disoproxil marketed
Veklury Veklury marketed Nucleoside analog prodrug NS5, Replicase polyprotein 1ab Metabolic
Pegylated Interferon alpha-2a Pegylated Interferon alpha-2a marketed Interferon alpha Interferon-alpha receptor (IFNAR) Immunology, Virology, Oncology
Lamivudine Oral Solution Lamivudine Oral Solution marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase; Hepatitis B virus polymerase Infectious Disease
Reinforced preventive ARV therapy Reinforced preventive ARV therapy marketed
Cabotegravir Tablets, for oral use. Cabotegravir Tablets, for oral use. phase 3 Integrase strand transfer inhibitor (INSTI) HIV integrase Infectious Disease / Virology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 5 shared drug classes
  2. GlaxoSmithKline · 5 shared drug classes
  3. ViiV Healthcare · 3 shared drug classes
  4. Hoffmann-La Roche · 3 shared drug classes
  5. National Taiwan University Hospital · 3 shared drug classes
  6. Pfizer · 3 shared drug classes
  7. French National Agency for Research on AIDS and Viral Hepatitis · 3 shared drug classes
  8. Henogen · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for ANRS, Emerging Infectious Diseases:

Cite this brief

Drug Landscape (2026). ANRS, Emerging Infectious Diseases — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/anrs-emerging-infectious-diseases. Accessed 2026-05-16.

Related